期刊
METABOLOMICS
卷 8, 期 6, 页码 997-1011出版社
SPRINGER
DOI: 10.1007/s11306-011-0329-9
关键词
Galactosamine; Hepatotoxicity; Acute-liver injury; DILI; Biomarkers; Serum metabolic profiling; UPLC-MS/MS metabolomics
资金
- Fondo de Investigaciones Sanitarias (Institute of Health Carlos III) [06/0621, PS09/00526]
- Program Ramon y Cajal of Spanish Ministry
- Diputacion Foral de Bizkaia [612TK20100014]
- National Institute of Health [R01 AT004896]
- Centro de Investigacion Biomedica en Red en el Area tematica de Enfermedades Hepaticas y Digestivas (CIBERehd)
- Institute of Health Carlos III
A key interest in clinical diagnosis and pharmaceutical industry is to have a repertoire of noninvasive biomarkers to-individually or in combination-be able to infer or predict the degree of liver injury caused by pathological conditions or drugs. Metabolomics-a comprehensive study of global metabolites-has become a highly sensitive and powerful tool for biomarker discovery thanks to recent technological advances. An ultra-performance liquid chromatography/time-of-flight tandem mass spectrometry (UPLC/TOF MS/MS)-based metabolomics approach was employed to investigate sera from galactosamine-treated rats to find potential biomarkers for acute liver injury. Hepatic damage was quantified by determining serum transaminase activity and in situ liver histological lesions. Principal component analysis in combination with coefficient of correlation analysis was used for biomarker selection and identification. According to the data, serum levels of several metabolites including glucose, amino acids, and membrane lipids were significantly modified, some of them showing a high correlation with the degree of liver damage determined by histological examination of the livers. In conclusion, this study supports that UPLC-MS/MS based serum metabolomics in experimental animal models could be a powerful approach to search for biomarkers for drug- or disease-induced liver injury.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据